Therapeutic ERCP — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Therapeutic ERCP (endoscopic retrograde cholangiopancreatography) is an advanced endoscopic procedure that combines upper gastrointestinal endoscopy with real-time fluoroscopic X-ray imaging to access, visualise, and treat diseases of the bile ducts (biliary tree) and pancreatic duct. A side-viewing duodenoscope is passed through the mouth, oesophagus, and stomach into the duodenum to reach the ampulla of Vater — the common opening of the bile duct and pancreatic duct into the duodenum. A catheter and guidewire are then advanced into the selected duct under fluoroscopic guidance, enabling a range of therapeutic interventions including stone extraction, stent placement, sphincterotomy, tissue sampling, and stricture dilation, all without the need for open surgery. Diagnostic ERCP — pure imaging of the ducts — has largely been replaced by MRCP (magnetic resonance cholangiopancreatography), a non-invasive MRI technique. Today, ERCP is almost exclusively performed with a therapeutic intent on the basis of a previously confirmed diagnosis from imaging. ERCP is recognised as a technically demanding procedure requiring specific training; quality metrics including selective cannulation success rate (target >90%) and complication rates are monitored by accreditation bodies internationally. It is one of the most technically demanding endoscopic procedures.

Therapeutic ERCP is indicated for conditions affecting the biliary tree and pancreatic duct that are accessible to endoscopic treatment. Biliary indications include: common bile duct stones (choledocholithiasis) causing obstructive jaundice, biliary colic, cholangitis, or pancreatitis — ERCP with sphincterotomy and stone extraction is the first-line treatment; malignant biliary obstruction from pancreatic cancer, cholangiocarcinoma, or metastatic disease — palliative biliary stenting restores bile flow and relieves jaundice without surgery; benign biliary strictures from primary sclerosing cholangitis, post-surgical anastomotic stricture, or chronic pancreatitis — treated with serial dilation and/or stent placement; bile leaks after laparoscopic cholecystectomy or hepatic surgery — treated with biliary stenting to decompress the leak; and ampullary adenoma removal (endoscopic papillectomy). Pancreatic indications include: pancreatic duct stones causing recurrent acute pancreatitis or pain from chronic pancreatitis — treated with stone extraction and lithotripsy; pancreatic duct strictures causing upstream dilation and pain — managed with stenting; and pancreatic pseudocysts communicating with the duct. Contraindications include uncorrected coagulopathy (INR >1.5), haemodynamic instability, severe cardiorespiratory compromise, and Roux-en-Y gastric bypass or other altered anatomy that prevents access to the ampulla (requiring surgical or double-balloon enteroscopy-assisted ERCP in such cases).

The patient fasts for 6–8 hours before the procedure. ERCP requires deep sedation or general anaesthesia because the patient must be still for 45–90 minutes in the prone or left lateral position while the endoscopist performs delicate intraluminal manoeuvres under fluoroscopy. The side-viewing duodenoscope (larger than a standard gastroscope, with an elevator mechanism for directing accessories) is advanced to the second part of the duodenum. The ampulla is identified and cannulated selectively — most commonly the bile duct — using a sphincterotome catheter. Contrast is injected under fluoroscopy to opacify the duct and identify filling defects (stones), strictures, or dilation. For stone extraction: a sphincterotomy is made at the papillary orifice by cutting the sphincter with electrosurgical current, enlarging the duct opening. Stones are then extracted with a balloon catheter (balloon swept down the duct, inflated, and pulled through) or Dormia basket. Large stones may require mechanical lithotripsy (fragmentation within the duct) or extracorporeal shock wave lithotripsy (ESWL) before extraction. For stent placement: a guidewire is advanced across the stricture and a plastic or self-expanding metal stent (SEMS) is deployed over the wire. Rectal indomethacin 100 mg is administered immediately before or after all ERCP procedures to reduce post-ERCP pancreatitis risk.

Therapeutic ERCP has transformed the management of biliopancreatic diseases, replacing open bile duct surgery for the majority of conditions. Bile duct stone clearance is achieved in over 90% of cases in expert centres at the first ERCP; second-session clearance raises cumulative success rates above 95% even for large or multiple stones. This avoids the morbidity and mortality of open bile duct exploration, which carries substantially higher complication rates. Biliary stenting for malignant obstruction achieves jaundice relief and restoration of bile flow in over 95% of technically successful procedures, significantly improving quality of life and enabling further oncological treatment such as chemotherapy. For post-cholecystectomy bile leak — a feared complication of laparoscopic cholecystectomy — biliary stenting achieves complete leak resolution in over 90% of cases without reoperating. ERCP-guided treatment of chronic pancreatitis complications (duct stones, strictures, pseudocysts) reduces pain and hospitalisation frequency in the majority of appropriately selected patients. The endoscopic approach eliminates the risks of laparotomy — wound infection, hernia, prolonged ileus, and general surgical risk — making ERCP particularly valuable in elderly and high-risk patients who could not tolerate open surgery.

ERCP carries the highest complication rate of any standard gastrointestinal endoscopic procedure, primarily because of manipulation within the pancreatic duct orifice. Post-ERCP pancreatitis (PEP) is the most common complication, occurring in 3–5% of all ERCPs and up to 15–25% in high-risk patients (young women, sphincter of Oddi dysfunction, difficult cannulation). PEP ranges from mild (elevated amylase with 24-hour pain) to severe necrotising pancreatitis requiring critical care. Rectal indomethacin administered pre- or peri-procedure reduces PEP risk by 40–60% and is now standard of care. Haemorrhage after sphincterotomy occurs in 1–2% and is usually mild and self-limiting, but may occasionally require adrenaline injection or angiographic embolisation. Cholangitis (biliary infection) occurs in 1–3%, particularly when drainage is incomplete or contaminated contrast has been injected into an undrained system; managed with antibiotics and repeat drainage. Perforation of the duodenum or bile duct (retroperitoneal or intraperitoneal) occurs in 0.1–0.6% and may require surgical repair. Stent-related complications include migration (5%), occlusion by sludge or tumour ingrowth, and cholecystitis from cystic duct orifice obstruction by a stent. Overall serious complication rate is approximately 5–10%; mortality directly attributable to ERCP is less than 0.5% in expert centres.

After ERCP, patients are monitored in a recovery area for 4–6 hours while sedation wears off, and until they are alert, comfortable, and haemodynamically stable. Blood is taken for serum amylase and liver function tests post-procedure; a significantly elevated amylase with clinical symptoms defines post-ERCP pancreatitis. A low-fat diet is recommended for 24–48 hours post-procedure regardless of complications. Most patients are discharged the same day for elective procedures, or after one overnight stay for more complex interventions or in patients with cholangitis requiring IV antibiotics. Patients should not drive for 24 hours after sedation. Return to normal diet and activities is typically within 1–3 days. Patients with plastic biliary stents require follow-up at 3 months for planned stent exchange, as plastic stents invariably occlude with biliary sludge by 3–4 months — occlusion causes jaundice and cholangitis. Self-expanding metal stents (SEMS) have a median patency of 6–12 months and are used for malignant obstruction. Patients should seek urgent medical attention for fever above 38°C, worsening abdominal pain, jaundice, vomiting, or rigors in the weeks following ERCP.